Entera Bio Ltd. (ENTX)
Chart Events
Performance Outlook
| Previous Close | 2.2800 |
| Open | 2.2900 |
| Bid | 2.3200 x 1300 |
| Ask | 2.3500 x 2200 |
| Day's Range | 2.2600 - 2.4500 |
| 52 Week Range | 1.2200 - 10.1600 |
| Volume | |
| Avg. Volume | 118,774 |
| Market Cap | 68.219M |
| Beta (5Y Monthly) | 1.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8290 |
| Earnings Date | Mar 16, 2022 - Mar 21, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.00 |
Fair Value
Related Research
- Entera Bio Ltd.Analyst Report: Microsoft CorporationMicrosoft develops and licenses consumer and enterprise software. It is known for its Windows operating systems and Office productivity suite. The company is organized into three equally sized broad segments: productivity and business processes (legacy Microsoft Office, cloud-based Office 365, Exchange, SharePoint, Skype, LinkedIn, Dynamics), intelligence cloud (infrastructure- and platform-as-a-service offerings Azure, Windows Server OS, SQL Server), and more personal computing (Windows Client, Xbox, Bing search, display advertising, and Surface laptops, tablets, and desktops).RatingFair ValueEconomic Moat16 hours agoMorningstar
- GlobeNewswire
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint
‒ Company plans to initiate multi-national Phase 3 Trial in 2022 ‒BOSTON and JERUSALEM, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), today announced it has concluded its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on EB613, its oral formulation of human parathyroid hormone (1-34), or PTH, for the treatment of osteoporosis and defined the path for Phase 3 development of EB613, confirming that a fracture study will not be necessary and that
- GlobeNewswire
Entera Bio Reports Third Quarter 2021 Financial Results
‒ Two Presentations at ASBMR, including Late Breaker, on Phase 2 EB613 Clinical Trial Results in Osteoporosis ‒ ‒ Study Sets Stage for Phase 3 registrational trial in 2022 ‒ BOSTON and JERUSALEM, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced financial and operating results for the third quarter ended September 30, 2021. Third Quarter 2021 and Recent Highlights Phase 2 EB613 (oral PTH
- GlobeNewswire
Entera Bio Publishes Key Study Describing its Oral Delivery Technology Platform for Biologic Drugs
‒Study describes a dual mechanism of action approach to oral drug delivery of large molecules, the “Holy Grail” of drug development. ‒Technology is utilized in Entera’s EB613 oral PTH drug for osteoporosis and several other molecules now in development by Entera and in collaboration with pharmaceutical companies. BOSTON and JERUSALEM, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), today announced that researchers at the company and the University of East Anglia in the UK publi
